Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 16/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 13/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.34 |
| ▸ | CCR6 | P51684 | 2/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207786 | 0.89 | CXCR2 (0.41) | CXCR2CXCR1CXCR3CCR6CCR4 | |
| SCHEMBL14100447 | 0.89 | CXCR2 (0.41) | CXCR2CXCR1CXCR3CCR6CCR4 | |
| SCHEMBL13227417 | 0.87 | CXCR1 (0.44) | CXCR2CXCR1CXCR3CCR6CCR4 | |
| SCHEMBL13227260 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1 | |
| SCHEMBL13227272 | 0.83 | CXCR2 (0.41) | CXCR2CXCR1CXCR3CCR6CCR4 | |
| SCHEMBL13227496 | 0.80 | CXCR2 (0.59) | CXCR2CXCR1 | |
| SCHEMBL13207775 | 0.79 | CXCR2 (0.42) | CXCR2CXCR1TRPV1 | |
| SCHEMBL13207777 | 0.79 | CXCR2 (0.46) | CXCR2CXCR1CCR6 | |
| SCHEMBL13227414 | 0.79 | CXCR2 (0.46) | CXCR2CXCR1CCR6 | |
| SCHEMBL13207779 | 0.79 | CXCR2 (0.52) | CXCR2CXCR1CXCR3CCR6CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | CXCR2 6/4885CXCR1 4/4885CXCR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.